Observational studyClinical and translational science2021
Autoantibodies in moderate and critical cases of COVID-19.
Observational study in Clinical and translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The Possible Role of Antibodies in Alopecia: A Narrative Review.Antibodies (Basel, Switzerland) · 2026Review
- Detection of autoantibodies in severe COVID-19 patients two years after hospital discharge.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2025Article
- The Onset of Antinuclear Antibodies (ANAs) as a Potential Risk Factor for Mortality and Morbidity in COVID-19 Patients: A Single-Center Retrospective Study.Biomedicines · 2024Article
- Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review.American journal of medicine open · 2024Article
- Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019.The Korean journal of internal medicine · 2023Article
- Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection.International immunopharmacology · 2022Review
- Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures.Allergy · 2022Article
- Clinical Phenotypes and Mortality Biomarkers: A Study Focused on COVID-19 Patients with Neurological Diseases in Intensive Care Units.Behavioral sciences (Basel, Switzerland) · 2022Article
- Immunological evaluation of patients with 2019 novel coronavirus pneumonia: CD4+ and CD16+ cells may predict severity and prognosis.PloS one · 2022Article
- Detection of Antinuclear Antibodies Targeting Intracellular Signal Transduction, Metabolism, Apoptotic Processes and Cell Death in Critical COVID-19 Patients.Mediterranean journal of hematology and infectious diseases · 2022Article
- Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis.Journal of immunological methods · 2021Article
- Antinuclear antibodies in COVID 19.Clinical and translational science · 2021Article
- A scoping review of the pathophysiology of COVID-19.International journal of immunopathology and pharmacologyArticle
- Assessment of background levels of autoantibodies as a prognostic marker for severe SARS-CoV-2 infection.Journal of circulating biomarkersArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.